For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Quick, we must do nothing
+Opinion
Quick, we must do nothing
Wednesday 5 February 2020, 01:39 PM

The art of doing nothing in the face of pressure to do something
A new study reinforces Jim Vause’s conviction that doing nothing is often just what the doctor should do
When “we must do something” combines with medical technology, the likelihood of significant harm increases exponentially
I’m not quite sure why I
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.